Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes.

Ding, Jia-Tong; Yang, Kang-Ping; Lin, Kong-Lan; Cao, Yu-Ke; Zou, Fang

Ding, Jia-Tong; Yang, Kang-Ping; Lin, Kong-Lan; Cao, Yu-Ke; Zou, Fang.

Afiliación

Ding JT; Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yang KP; The Second Clinical Medicine School, Nanchang University, Nanchang, China.
Lin KL; The Second Clinical Medicine School, Nanchang University, Nanchang, China.
Cao YK; The Second Clinical Medicine School, Nanchang University, Nanchang, China.
Zou F; School of Ophthalmology & Optometry, Nanchang University, Nanchang, China.

Front Endocrinol (Lausanne) ; 13: 1090842, 2022.

Article en En | MEDLINE | ID: mdl-36704045

Asunto(s)

Diabetes Mellitus Tipo 1; Neoplasias; Humanos; Proteínas de Punto de Control Inmunitario; Diabetes Mellitus Tipo 1/tratamiento farmacológico; Inhibidores de Puntos de Control Inmunológico/uso terapéutico; Neoplasias/metabolismo; Inmunoterapia

Palabras clave

immune checkpoint inhibitors; immune checkpoints; immunotherapy; lymphocyte; type 1 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Neoplasias Límite: Humans Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google